« Back
Regulatory T-Cells (Tregs) Within Bone Marrow-Derived Stem Cells (BMSCs) Actively Confer Immunomodulatory and Neuroprotective Effects Against Stroke
Poster Title: Regulatory T-Cells (Tregs) Within Bone Marrow-Derived Stem Cells (BMSCs) Actively Confer Immunomodulatory and Neuroprotective Effects Against Stroke
Submitted on 08 Feb 2018
Author(s): Elliot Neal, MS1; Sandra A. Acosta, MS PhD1; Yuji Kaneko, PhD1; Cesario V. Borlongan, MA PhD1
Affiliations: 1Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, Florida
This poster was presented at USF Research Day 2018
Poster Views: 474
View poster »

Poster Information
Abstract: Stroke is the second leading cause of death worldwide and the third major cause of adult disability in adults. Regulatory T-cells (Tregs) may exert a neuroprotective effect on ischemic stroke by inhibiting both inflammation and effector T-cell activation. Transplantation of human bone marrow-derived stem cells (BMSCs) in ischemic stroke affords neuroprotection that results in part from the cells’ anti-inflammatory property. However, the relationship between Tregs and BMSCs in treatment of ischemic stroke has not been fully elucidated.
Immunocytochemistry (ICC) and flow cytometry were used to identify cells expressing phenotypic markers of Tregs: CD4, CD25, and FoxP3 protein. Tregs were isolated using magnetic sorting from murine spleens. Primary rat neuronal cells (PRNCs) were subjected to an oxygen-glucose deprivation and reperfusion (OGD/R) condition. The cells were re-perfused and co-cultured with Tregs and/or BMSCs. We measured neuronal cell viability using ICC with Hoechst and MAP2.
We detected a minority population of Tregs within BMSCs with both ICC and flow cytometry. PRNCs were protected from OGD/R when co-cultured with BMSCs containing varying proportions of Tregs. The BMSC treatment containing the native population of Tregs conferred maximal neuroprotection compared to the treatment conditions containing 0%, 10%, and 100% relative ratio Tregs. Increasing the Treg population resulted in increased IL-6 secretion and decreased FGF-beta secretion by BMSCs.
BMSC transplantation stands as a potent treatment for ischemic stroke. Modulation of the immune system is a key mechanism by which BMSCs confer neuroprotection. This study shows that a minority population of Tregs exists within the therapeutic BMSC population, and those Tregs are robust mediators of the immunomodulatory effect provided by BMSC transplantation. The ratio of Tregs found naturally in BMSCs correlates with the highest level of neuroprotection after ischemic stroke.
Summary: We found a distinct subpopulation of Tregs within BMSCs. Tregs and BMSCs in co-culture conferred neuroprotection that varied in a dose-dependent manner. Tregs minimized stem cell production of IL-6, a pro-inflammatory cytokine, and inhibited BMSC secretion of FGF-beta, a cytokine related to BMSC proliferation and differentiation. The ratio of Tregs found natively in BMSCs is optimally adapted to provide the maximum neuroprotective benefit of stem cell treatment after ischemic stroke.References: N/AReport abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Etiological diagnostics of cardiomyopathies in the cardiology unit of the HUEH internal medicine department during the period from 8 January 2014 to 14 June 2014
*Axler JEAN PAUL; **Lesly Ed. ARCHER; *Raema Mimrod JEAN; *Gerald VERNELUS; *Rodolph MALEBRANCHE

Medical Student: Move over Stem Cells – Exosomes are Here! What are Exosomes & their role in Regenerative Medicine?
Amartej Singh Deol MD4 & Advisor: Shivinder S. Deol MD

Briand Bounkeu MD; Ravi Shekarappa MD; La Toya Jackson DO, FAAFP; Chinedu Ivonye MD, FACP; Cristal Kudiwu MD

Striving for Equity in Surgical, Anesthesia, and Obstetric Research in Haiti: A Multi-Partner, International Research Training Collaboration
Dr. Jean Alouidor*, Dr. Frédéric Barau Déjean*, Dr. Louis-Franck Télémaque, Dr. Ronald Eveillard, Dr. Laëlle Mangurat, Dr. Isaac Martineau, Dr. Chartelin Jean Isaac, Dr. Darlène Rochelin Paultre, Carine Réveil Jean-Baptiste, Dr. Lucile Louis Riché, Dr. Jordan Pyda, Rolvix Patterson III, Dr. Blake Alkire, Dr. Eunice Dérivois-Mérisier (*Co-First Authors)

Projektstatus: Entwicklung einer konsensbasierten Therapieempfehlung für die PADOVAN-METHODE® in der Neurorehabilitation
Eisenmeier, Dimitri1; Ostermann, Thomas1; Vogel, Hannah1; Fetz, Katharina1